BIOLASE, Inc. (NASDAQ:BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common stock and pre-funded warrants to purchase 11,403,571 shares of common stock at a public offering price of $0.35 per share or $0.34 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.01 per share, are exercisable immediately, and will not expire until exercised. The offering is expected to close on January 12, 2023, subject to customary closing conditions.
Remember Elon Musk And Christine Baranski’s Viral ‘Death Stare’ Met Gala Photo? Actress Finally Reveals What Was Going On
American actress and comedian Christine Baranski said that her cold stare at Tesla Inc (NASDAQ: TSLA) CEO Elon Musk during the Met Gala in May was fueled by disdain.
